Sorafenib reduces steatosis-induced fibrogenesis in a human3Dco-culture model of non-alcoholic fatty liver disease

Autor(es)

Romualdo, Guilherme Ribeiro ^[1] ; Da Silva, Tereza Cristina ^[2] ; de Albuquerque Landi, Marina Frota ^[2] ; Morais, Juliana Avila ^[2] ; Barbisan, Luis Fernando ^[1] ; Vinken, Mathieu ^[3] ; Oliveira, Claudia Pinto ^[4] ; Cogliati, Bruno ^[2]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Biosci Inst, Dept Struct & Funct Biol, Botucatu, SP - Brazil

^[2] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, Ave Prof Dr Orlando Marques de Paiva 87, Sao Paulo - Brazil

^[3] Vrije Univ Brussel, Fac Med & Pharm, Dept Vitro Toxicol & Dermatocosmetol, Brussels - Belgium

^[4] Univ Sao Paulo, Sch Med, Dept Gastroenterol LIM07, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: ENVIRONMENTAL TOXICOLOGY; v. 36, n. 2 SEP 2020.
• Citações Web of Science: 0

Resumo

Non-alcoholic fatty liver disease (NAFLD) affects around 25% of the worldwide population. Non-alcoholic steatohepatitis (NASH), the more progressive variant of NAFLD, is characterized by steatosis, cellular ballooning, lobular inflammation, and may culminate on hepatic stellate cell (HSC) activation, thus increasing the risk for fibrosis, cirrhosis, and HCC development. Conversely, the antifibrotic effects of sorafenib, an FDA-approved drug for HCC treatment, have been demonstrated in 2D cell cultures and animal models, but its mechanisms in a NAFLD-related microenvironment in vitro requires further investigation. Thus, a human 3D co-culture model of fatty hepatocytes and HSC was established by culturing hepatoma C3A cells, pre-treated with 1.32 mM oleic acid, with HSC LX-2 cells. The fatty C3A/LX-2 spheroids showed morphological and molecular hallmarks of altered lipid metabolism and steatosis-induced fibrogenesis, similarly to the human disease. Sorafenib (15 mu M) for 72 hours reduced fatty spheroid viability, and upregulated the expression of lipid oxidation- and hydrolysis-related genes,CPT1andLIPC, respectively. Sorafenib also inhibited steatosis-induced fibrogenesis by downregulatingCOL1A1,TGFB1,PDGF, andTIMP1and by decreasing protein levels of IL-6, TGF-beta 1, and TNF-alpha in fatty spheroids. The demonstration of the antifibrotic properties of sorafenib on steatosis-induced fibrogenesis in a 3D in vitro model of NAFLD supports its clinical use as a therapeutic agent for the treatment of NAFLD/NASH patients. (AU)

• Processo FAPESP: 12/17084-0 - Aspectos moleculares dos esferóides celulares no modelo 3D da doença hepática gordurosa não alcoólica (DHGNA)
• Beneficiário: Juliana Ávila Morais
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 10/50598-1 - Potencial terapêutico do doador de óxido nítrico s-nitroso-n- acetilcisteína (SNAC) em modelo in vitro da doença hepática gordurosa não alcoólica: avaliação do estímulo parácrino dos hepatócitos na...
• Beneficiário: Bruno Cogliati
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 11/18954-5 - Co-cultivo 3D de hepatócitos gordurosos e células estreladas: avaliação da fibrogênese induzida pela esteatose em modelo in vitro inédito da doença hepática gordurosa não alcoólica
• Beneficiário: Bruno Cogliati
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 11/18461-9 - Avaliação morfológica e ultraestrutural dos esferóides celulares em modelo 3D da doença hepática gordurosa não alcoólica in vitro
• Beneficiário: Marina Frota de Albuquerque Landi
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica